# A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults

> **NCT02633839** · PHASE1 · COMPLETED · sponsor: **Acorda Therapeutics** · enrollment: 60 (actual)

## Conditions studied

- Smoking

## Interventions

- **DRUG:** CVT-301
- **DRUG:** Carbidopa

## Key facts

- **NCT ID:** NCT02633839
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2016-04
- **Final completion:** 2016-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02633839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02633839, "A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults". Retrieved via AI Analytics 2026-09-12 from https://api.ai-analytics.org/clinical/NCT02633839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*